NOWINY LEKARSKIE 4 - Nowiny Lekarskie - UMP

Nowe leki przeciwnadciśnieniowe z grupy antagonistów kanałów wapniowych (A-Ca 2+ ) 37731. Iimura O., Shimamoto K., Masuda A. i wsp.: Effect of calciumchannel blocker, manidipine, on insulin sensitivity inessential hypertensives. J. Diabetes Complications. 1995, 9,4, 215–219.32. Ueshiba H., Miyachi Y.: Effects of manidipine hydrochlorideon steroid hormones and insulin in hypertensive patients withobesity. Ther. Res., 2002, 23, 10, 2071–2076.33. Viviani G.L.: Lercanidipine in type 2 diabetic patients withmild to moderate arterial hypertension. J. Cardiovasc. Pharmacol.,2002, 40, 1, 133–139.34. Roth M., Keul R., Perruchoud A.P. i wsp.: Manidipine affectsrPDF-BB-induced gene transcription of low-density lipoproteinreceptors and 3-hydroxy-3-methylglutaryl coenzymeA reductase in human mesangial cells. Am. Heart J., 1993,125, 598–603.35. 35. Canavesi M, Baldini N, Leonardi A, Sironi G, Bellosta S,Bernini F.: In vitro inhibitory effect of lercanidipine on cholesterolaccumulation and matrix metalloproteinases secretionby macrophages. J. Cardiovasc. Pharmacol., 2004, 44, 4,416–422.36. Corsini A, Accomazzo MR, Canavesi M. i wsp.: The newcalcium antagonist lercanidipine and its enantiomers effectmajor processes of atherogenesis in vitro: is calcium entry involved? Blood Press., 1998, 2, 18–22.37. Calo L.A., Zaghetto F., Pagnin E. i wsp.: Effects of manidipineon gene expression and protein level of oxidative stressrelatedproteins: p22phox and HO-1. J. Cardiovasc. Pharmacol.,2004, 43, 4, 531–538.38. Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G.,Magagna A., Salvetti A.: Calcium antagonist treatment bylercanidipine prevents hyperpolarisation in essential hypertension.Hypertension, 2003, 41, 4, 950–955.39. Cominacini L, Fratta-Pasini A, Garbin U, Pastorino AM, DavoliA, Nava C i wsp.: Antioxidant activity of different dihydropyridines.Biochem. Biophys. Res. Commun., 2003, 302,4, 679–684.40. Fogari R., Zoppi A., Corradi L. i wsp: Effects of different dihydropyridinecalcium antagonists on plasma norepinephrinein essential hypertension. J. Hypertens., 2000, 18, 1871–1875.41. Grassi G., Seravalle G., Turri C. i wsp.: Short- versus longtermeffects of different dihydropyridines on sympathetic andbaroreflex function in hypertension. Hypertension. 2003, 41,3, 558–562.42. Del Vecchio L, Pozzi M, Salvetti A. i wsp.: Efficacy and tolerabilityof manidipine in the treatment of hypertension inpatients with non-diabetic chronic kidney disease withoutglomerular disease: prospective, randomized, double-blindstudy of parallel groups in comparison with enalapril.J. Nephrol., 2004, 17, 261–269.43. Romito R., Pansini M.I., Perticone F., Antonelli G., PitzalisM., Rizzon P.: Comparitive effect of lercanidipine, felodipine,and nifedipine GITS on blood pressure and heart rate inpatients with mild to moderate arterial hypertension: the Lercanidipinein Adults (LEAD) Study. J. Clin. Hypertens.,2003, 5, 4, 249–253.44. Barrios V., Navarro A., Esteras A. i wsp.: Antihypertensiveefficacy and tolerability of lercanidipine in daily clinical practise.The ELYPSE study. Blood Press., 2002, 11, 2, 95–100.45. Schwinger R.H.G., Schmidt-Mertens A.: The new lipophiliccalcium channel blocker lercanidipine combines high antihypertensiveefficacy with low side effects [abstract no. P1-7].Dtsch. Med. Wochenschr., 2002, 127 Suppl.1, S13.46. Fogari R., Mugellini A., Zoppi A. i wsp.: Differential effectsof lercanidipine and nifedipine GITS on plasma norepinephrinein chronic treatment of hypertension. Am. J. Hypertens.,2003, 16, 7, 596–599.47. Casiglia E, Mazza A, Tikhonoff V, Basso G, Martini B,Scarpa R, Pessina AC.: Therapeutic profile of manidipine andlercanidipine in hypertensive patients. Adv. Ther., 2004, 21,6, 357–369.48. Pedrinelli R., Dell’Omo G., Nuti M., Menegato A., BalbariniA., Mariani M.: Heterogeneous effect of calcium antagonistson leg oedema: a comparison of amlodipine versus lercanidipinein hypertensive patients. Hypertens., 2003, 21, 10, 1969–1973.49. Borghi C., Prandin M.G., Dormi A., Ambrosioni E.: Improvedtolerability of the dihydropyridine calcium-channelantagonist lercanidipine: the lercanidipine challenge trial.Blood. Press., Suppl., 2003;Suppl 1, 14–21.50. Millar-Craig M, Shaffu B, Greenough A, Mitchell L, McDonaldC.: Lercanidipine vs lacidipine in isolated systolic hypertension.J. Human. Hypertens., 2003, 17, 11, 799–806.51. Cherubini A., Fabris F., Ferrari E., Cucinotta D., Incalzi R.A.,Senin U.: Comparative effects of lercanidipine, lacidipine,and nifedipine gastrointestinal therapeutic system on bloodpressure and heart rate in elderly hypertensive patients: theELderly and LEcarnidipine (ELLE) study. Arch. Gerontol.Geriatr., 2003, 37, 203–212.52. Poncelet P., Ribstein J., Goullard L., Bassous M., Gres C.S.,Clerson P.: Efficacy and acceptability of lercanidipine are notage dependent in patients with essential hypertension: theAGATE study. Ann. Cardiol. Angeiol., 2004, 53, 3, 123–130.53. Fogari R., Zoppi A., Lusardi P. i wsp.: Evaluation by 24-hambulatory blood pressure monitoring of efficacy of manidipinehydrochloride 10, 20 or 40 mg once daily as comparedto placebo in treating mild-to-moderate essential hypertension:a double-blind, randomized, parallel group, placebocontrolledstudy. Blood Press., 1996, 5, S16–23.54. Fogari R., Zoppi A., Lusardi P. i wsp.: Efficacy and tolerabilityof manidipine hydrochloride in the long-term treatmentof mild-to-moderate hypertension. Blood Press., 1996, 5,S24–28.55. Ogihara T., Nakagawa M., Ishikawa H. i wsp: Effect of manidipine,a novel calcium channel blocker, on quality of lifein hypertensive patients. Blood Press., 1992, 3, S135–139.56. Zanchetti A., Omboni S., Commare P. i wsp.: Efficacy, tolerabilityand impact on quality of life and long-term treatmentwith manidipine or amlodipine in patients with essentialhypertension. J. Cardiovasc. Pharmacol., 2001, 38, 642–650.57. Kaneko Y., Fukiyama K., Iimura O. i wsp.: Clinical study ofmanidipine hydrochloride in essential hypertension: a doubleblindcontrolled study with nicardipine hydrochloride.J. Clin. Exp. Med., 1989, 151, 8, 471–492.58. Ogihara T.: Practitioner’s trial on the efficacy of AntihypertensiveTreatment in the Elderly-Hypertension (the PATE-Hypertension study) in Japan. Am. J. Hypertens., 2000, 13, 5,461–467.59. Nagasawa K., Kitamoto K., Nagasawa T.: A 3-year longtermevaluation of the efficacy and safety of manidipine hydrochloride(Calslot tablet) in the elderly patients with essentialhypertension: a multicenter collaborative study. RinshoKetsueki, 1997, 74, 10, 2630–2638.60. Zanchetti A.: Emerging data on calcium-channel blockers:the COHORT study. Clin. Cardiol., 2003, 26, 2 Suppl 2,II17–20.